96 related articles for article (PubMed ID: 9574473)
1. The expression and localization of Scl-70/DNA topoisomerase I vary throughout the cell cycle.
Ramirez-Santoyo R; Lopez-Swiderski A; Avalos-Diaz E; Herrera-Esparza R
Rev Rhum Engl Ed; 1998 Mar; 65(3):165-72. PubMed ID: 9574473
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
3. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
4. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
6. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I.
Buckwalter CA; Lin AH; Tanizawa A; Pommier YG; Cheng YC; Kaufmann SH
Cancer Res; 1996 Apr; 56(7):1674-81. PubMed ID: 8603419
[TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP
Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520
[TBL] [Abstract][Full Text] [Related]
8. Behavior of nuclear matrix proteins during camptothecin-induced apoptosis in HL-60 human leukemia cells.
Zweyer M; Bareggi R; Grill V; Soranzo MR; Marugg RA; Riederer BM; Narducci P; Martelli AM
Exp Cell Res; 1995 Nov; 221(1):27-40. PubMed ID: 7589253
[TBL] [Abstract][Full Text] [Related]
9. Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death.
Sané AT; Bertrand R
Cancer Res; 1999 Aug; 59(15):3565-9. PubMed ID: 10446962
[TBL] [Abstract][Full Text] [Related]
10. Dynamic changes in subnuclear NP95 location during the cell cycle and its spatial relationship with DNA replication foci.
Miura M; Watanabe H; Sasaki T; Tatsumi K; Muto M
Exp Cell Res; 2001 Feb; 263(2):202-8. PubMed ID: 11161719
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of DNA replication in extracts of camptothecin-treated cells: activation of an S-phase checkpoint?
Wang Y; Perrault AR; Iliakis G
Cancer Res; 1997 May; 57(9):1654-9. PubMed ID: 9135002
[TBL] [Abstract][Full Text] [Related]
12. Developmental activation of the capability to undergo checkpoint-induced apoptosis in the early zebrafish embryo.
Ikegami R; Hunter P; Yager TD
Dev Biol; 1999 May; 209(2):409-33. PubMed ID: 10328930
[TBL] [Abstract][Full Text] [Related]
13. [Apoptosis of nasopharyngeal carcinoma cells induced by topoisomerase I inhibitor].
Zhang Q; Zhou K; Ling G
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1997 Dec; 32(6):332-5. PubMed ID: 10743104
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
15. Recruitment of topoisomerase I (Scl-70) to nucleoplasmic proteasomes in response to xenobiotics suggests a role for altered antigen processing in scleroderma.
Chen M; Dittmann A; Kuhn A; Ruzicka T; von Mikecz A
Arthritis Rheum; 2005 Mar; 52(3):877-84. PubMed ID: 15751092
[TBL] [Abstract][Full Text] [Related]
16. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
Danks MK; Pawlik CA; Whipple DO; Wolverton JS
Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
[TBL] [Abstract][Full Text] [Related]
17. E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin.
Dong YB; Yang HL; McMasters KM
Cancer Gene Ther; 2003 Mar; 10(3):168-78. PubMed ID: 12637937
[TBL] [Abstract][Full Text] [Related]
18. Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
Chen BM; Chen JY; Kao M; Lin JB; Yu MH; Roffler SR
Gynecol Oncol; 2000 Nov; 79(2):272-80. PubMed ID: 11063656
[TBL] [Abstract][Full Text] [Related]
19. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
[TBL] [Abstract][Full Text] [Related]
20. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system.
Tsao YP; Russo A; Nyamuswa G; Silber R; Liu LF
Cancer Res; 1993 Dec; 53(24):5908-14. PubMed ID: 8261402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
